Protolabs Q2 2026 Earnings: Record Revenue Drives Margin Expansion

TradingKey
07/31

Protolabs (NYSE: PRLB) reported Q2 2026 revenue of $149.3 million, up 10.6% from $135.1 million a year earlier, while GAAP diluted EPS rose to $0.37 from $0.18. Net income more than doubled and both gross and operating margins expanded, with CNC machining and injection molding providing the main growth while 3D printing declined.

Core financial results

Record revenue was accompanied by faster profit growth. GAAP gross profit increased approximately 16%, while operating income rose about 129% as revenue growth and gross-margin expansion outpaced the increase in operating expenses.

Adjusted measures moved in the same direction. Non-GAAP operating margin increased by 3.4 percentage points, and adjusted EBITDA rose 27.6% to $25.1 million.

MetricQ2 2026Q2 2025Year-over-year change
Revenue$149.3M$135.1M+10.6%
GAAP gross profit / margin$69.3M / 46.4%$59.8M / 44.3%Approx. +16.0%; margin +2.1 pts
GAAP operating income / margin$11.4M / 7.6%$5.0M / 3.7%Approx. +128.6%; margin +3.9 pts
GAAP net income$9.2M$4.4MApprox. +106.7%
GAAP diluted EPS$0.37$0.18Approx. +105.6%
Non-GAAP diluted EPS$0.60$0.41Approx. +46.3%
Adjusted EBITDA / margin$25.1M / 16.8%$19.7M / 14.6%+27.6%; margin +2.2 pts

Non-GAAP results exclude items including stock-based compensation, amortization, restructuring and transformation costs, exit-related costs, foreign-currency effects, and certain other adjustments.

Business and segment performance

CNC machining and injection molding generated nearly all of the service-line growth. Together, the two businesses produced $124.0 million of quarterly revenue, while 3D printing declined and sheet metal posted modest growth.

Service lineQ2 2026 revenueQ2 2025 revenueYear-over-year change
CNC machining$70.4M$61.9M+13.6%
Injection molding$53.6M$47.4M+13.1%
3D printing$20.7M$21.2M-2.6%
Sheet metal$4.5M$4.3M+3.7%

Total revenue per customer contact increased 16.7%. Management said larger strategic customers were expanding their relationships with Protolabs, supporting the increase in revenue generated per customer interaction.

Growth was also broad across the company’s reported regions. U.S. revenue increased 10.9% to $122.8 million, while Europe revenue rose 9.2% to $26.6 million. On a constant-currency basis, European growth was 7.3% and total company growth was 10.2%, compared with reported growth of 10.6%.

Revenue growth outpaced costs, producing operating leverage

The quarter’s most important profitability development was the gap between revenue and expense growth. Revenue increased 10.6%, while total operating expenses rose approximately 5.8% to $58.0 million. Combined with the higher gross margin, this caused operating income to more than double.

The improvement was visible under both accounting measures rather than being driven solely by exclusions. GAAP operating margin expanded 3.9 percentage points, compared with a 3.4-point increase in non-GAAP operating margin. That occurred even though the quarter included $0.9 million of restructuring and transformation costs and another $0.9 million of exit and disposal costs.

The difference between GAAP and non-GAAP earnings remained meaningful. Non-GAAP diluted EPS of $0.60 exceeded GAAP diluted EPS of $0.37, principally because the adjusted calculation excluded stock-based compensation, amortization, restructuring and exit costs, and other specified items.

Cash flow and balance sheet

Protolabs generated $15.4 million of operating cash flow during the quarter. For the first six months of 2026, operating cash flow was $33.0 million, up from $29.0 million in the comparable 2025 period. These figures should not be mixed: the $15.4 million amount is quarterly, while the $33.0 million amount covers the first half of the year.

First-half capital spending increased to $9.7 million from $2.7 million. Changes in operating assets and liabilities used $12.7 million of cash, compared with $1.0 million a year earlier, partly limiting the cash-flow benefit from higher net income.

Cash and investments totaled $162.9 million at June 30, 2026. Cash and cash equivalents increased to $127.9 million from $110.8 million at the end of 2025. Over the same period, accounts receivable rose to $95.1 million from $79.0 million, while inventory increased to $15.4 million from $14.4 million.

Guidance

Protolabs raised its full-year revenue growth range by two percentage points at both ends, the clearest forward-looking change in the release. It also issued Q3 ranges for revenue and GAAP and non-GAAP diluted EPS.

MetricLatest guidancePrevious guidanceChange
Full-year 2026 revenue growth8%-10%6%-8%Raised by 2 pts at both ends
Q3 2026 revenue$145M-$153MNot providedNew range
Q3 2026 GAAP diluted EPS$0.34-$0.42Not providedNew range
Q3 2026 non-GAAP diluted EPS$0.56-$0.64Not providedNew range

The Q3 revenue midpoint is $149 million, approximately level with Q2’s record $149.3 million. The guidance therefore supports higher full-year growth while indicating limited sequential revenue growth at the third-quarter midpoint.

Recent insider transactions

The supplied six-month insider summary reports purchases of 84,135 shares across 16 transactions and sales of 33,163 shares across five transactions. That produced net purchases of 50,972 shares, equal to 19.5% of the reported 312,650 total insider shares held.

The latest individual records include stock awards, a derivative-security exercise and sales. Stock awards recorded at $0 are compensation grants rather than open-market purchases.

DateInsider and roleTransactionReported price per shareReported value
June 2, 2026Sven A. Wehrwein, DirectorSale$76.91-$78.38$154,550
May 20, 2026Bernardo Parlange, OfficerStock award$0.00$0
May 19, 2026Donald G. Krantz, DirectorStock award$0.00$0
May 19, 2026Sujeet Chand, DirectorStock award$0.00$0
May 19, 2026Moonhie Chin, DirectorStock award$0.00$0
May 19, 2026Archie C. Black, DirectorStock award$0.00$0
May 19, 2026Rainer Gawlick, DirectorStock award$0.00$0
May 19, 2026Sven A. Wehrwein, DirectorStock award$0.00$0
May 12, 2026Michael R. Kenison, COOConversion or exercise of derivative security$33.52-$59.40$617,367
May 12, 2026Michael R. Kenison, COOSale$67.58-$70.30$1,636,166

The individual transaction data do not provide share quantities for these entries, so the reported values should not be treated as transaction volumes.

Risks investors need to watch

  • Growth remains uneven across services. Double-digit gains in CNC machining and injection molding offset a 2.6% decline in 3D printing. Continued overall growth therefore depends heavily on the two largest service lines.
  • Q3 guidance points to a stable sequential midpoint. The $149 million revenue midpoint is roughly unchanged from Q2, making the raised full-year outlook dependent on maintaining the first half’s growth momentum.
  • Cash conversion faces higher investment and working-capital demands. First-half capital spending increased substantially, while changes in operating assets and liabilities used $12.7 million of cash. Accounts receivable also grew faster than inventory between year-end and June 30.
  • The GAAP and adjusted earnings gap remains significant. Restructuring, exit costs, stock-based compensation and other exclusions contributed to non-GAAP EPS of $0.60 versus GAAP EPS of $0.37. The persistence of these items will affect how adjusted profitability translates into reported earnings.
  • Currency contributed to reported European growth. Europe grew 9.2% on a reported basis but 7.3% at constant currency, showing that exchange rates provided part of the regional increase.

Summary

Protolabs’ Q2 2026 results combined record revenue with materially better profitability, as CNC machining and injection molding growth, higher revenue per customer contact and slower expense growth produced operating leverage. The full-year revenue outlook was raised, but the Q3 midpoint implies little sequential growth. The main follow-up points are whether service-line growth broadens beyond the two largest businesses, margins remain elevated, and higher working-capital and capital-investment needs continue to allow solid cash generation.

Find out more

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10